✅ Öppen
Ingen deadline angiven
Läkemedel Infliximab 2024
Tidsplan
Publicerad
2025-01-13
Deadline
—
Beskrivning
Tilldelat till: Sandoz A/S, Orion Pharma Aktiebolag, Janssen-Cilag Aktiebolag | Vinnarland: SWE | Beslutsdatum: 2024-09-12+02:00
Klassificering
CPV-koder
- 33600000 Läkemedel
Procedur
open
Om köparen
Region Blekinge har 14 öppna upphandlingar på Agentanbud just nu, och 59 annonser i vår data.
Köper oftast: Medicinsk utrustning, läkemedel och hygienartiklar · Programvara och informationssystem · IT-tjänster: konsultverksamhet, programvaruutveckling, Internet och stöd.
Flest kontrakt 2021–2024, enligt Upphandlingsmyndighetens statistik över 181 kontrakterade anbud: Abena AB (9) · Essity Hygiene AND Health Aktiebolag (6) · Swereco AB (6).
Liknande öppna upphandlingar
Rådata (JSON)
{
"contract-duration-start-date-lot": [
"2025-01-01+01:00"
],
"title-proc": {
"swe": "Läkemedel Infliximab 2024"
},
"publication-number": "20411-2025",
"contract-conclusion-date": [
"2025-01-01+01:00",
"2025-01-01+01:00",
"2025-01-01+01:00",
"2025-01-01+01:00"
],
"winner-country": [
"SWE",
"SWE",
"SWE",
"SWE"
],
"organisation-country-buyer": [
"SWE"
],
"framework-agreement-lot": [
"fa-wo-rc"
],
"place-of-performance-country-proc": [
"SWE"
],
"winner-identifier": [
"2774-4532",
"556193-6294",
"556024-0037",
"556564-4308"
],
"procedure-type": "open",
"classification-cpv": [
"33600000",
"33600000"
],
"publication-date": "2025-01-13+01:00",
"buyer-name": {
"swe": [
"Region Blekinge"
]
},
"winner-decision-date": [
"2024-09-12+02:00",
"2024-09-12+02:00",
"2024-09-12+02:00",
"2024-09-12+02:00"
],
"contract-nature-main-proc": "supplies",
"links": {
"xml": {
"MUL": "https://ted.europa.eu/en/notice/20411-2025/xml"
},
"pdf": {
"BUL": "https://ted.europa.eu/bg/notice/20411-2025/pdf",
"SPA": "https://ted.europa.eu/es/notice/20411-2025/pdf",
"CES": "https://ted.europa.eu/cs/notice/20411-2025/pdf",
"DAN": "https://ted.europa.eu/da/notice/20411-2025/pdf",
"DEU": "https://ted.europa.eu/de/notice/20411-2025/pdf",
"EST": "https://ted.europa.eu/et/notice/20411-2025/pdf",
"ELL": "https://ted.europa.eu/el/notice/20411-2025/pdf",
"ENG": "https://ted.europa.eu/en/notice/20411-2025/pdf",
"FRA": "https://ted.europa.eu/fr/notice/20411-2025/pdf",
"GLE": "https://ted.europa.eu/ga/notice/20411-2025/pdf",
"HRV": "https://ted.europa.eu/hr/notice/20411-2025/pdf",
"ITA": "https://ted.europa.eu/it/notice/20411-2025/pdf",
"LAV": "https://ted.europa.eu/lv/notice/20411-2025/pdf",
"LIT": "https://ted.europa.eu/lt/notice/20411-2025/pdf",
"HUN": "https://ted.europa.eu/hu/notice/20411-2025/pdf",
"MLT": "https://ted.europa.eu/mt/notice/20411-2025/pdf",
"NLD": "https://ted.europa.eu/nl/notice/20411-2025/pdf",
"POL": "https://ted.europa.eu/pl/notice/20411-2025/pdf",
"POR": "https://ted.europa.eu/pt/notice/20411-2025/pdf",
"RON": "https://ted.europa.eu/ro/notice/20411-2025/pdf",
"SLK": "https://ted.europa.eu/sk/notice/20411-2025/pdf",
"SLV": "https://ted.europa.eu/sl/notice/20411-2025/pdf",
"FIN": "https://ted.europa.eu/fi/notice/20411-2025/pdf",
"SWE": "https://ted.europa.eu/sv/notice/20411-2025/pdf"
},
"pdfs": {
"SWE": "https://ted.europa.eu/sv/notice/20411-2025/pdfs"
},
"html": {
"BUL": "https://ted.europa.eu/bg/notice/-/detail/20411-2025",
"SPA": "https://ted.europa.eu/es/notice/-/detail/20411-2025",
"CES": "https://ted.europa.eu/cs/notice/-/detail/20411-2025",
"DAN": "https://ted.europa.eu/da/notice/-/detail/20411-2025",
"DEU": "https://ted.europa.eu/de/notice/-/detail/20411-2025",
"EST": "https://ted.europa.eu/et/notice/-/detail/20411-2025",
"ELL": "https://ted.europa.eu/el/notice/-/detail/20411-2025",
"ENG": "https://ted.europa.eu/en/notice/-/detail/20411-2025",
"FRA": "https://ted.europa.eu/fr/notice/-/detail/20411-2025",
"GLE": "https://ted.europa.eu/ga/notice/-/detail/20411-2025",
"HRV": "https://ted.europa.eu/hr/notice/-/detail/20411-2025",
"ITA": "https://ted.europa.eu/it/notice/-/detail/20411-2025",
"LAV": "https://ted.europa.eu/lv/notice/-/detail/20411-2025",
"LIT": "https://ted.europa.eu/lt/notice/-/detail/20411-2025",
"HUN": "https://ted.europa.eu/hu/notice/-/detail/20411-2025",
"MLT": "https://ted.europa.eu/mt/notice/-/detail/20411-2025",
"NLD": "https://ted.europa.eu/nl/notice/-/detail/20411-2025",
"POL": "https://ted.europa.eu/pl/notice/-/detail/20411-2025",
"POR": "https://ted.europa.eu/pt/notice/-/detail/20411-2025",
"RON": "https://ted.europa.eu/ro/notice/-/detail/20411-2025",
"SLK": "https://ted.europa.eu/sk/notice/-/detail/20411-2025",
"SLV": "https://ted.europa.eu/sl/notice/-/detail/20411-2025",
"FIN": "https://ted.europa.eu/fi/notice/-/detail/20411-2025",
"SWE": "https://ted.europa.eu/sv/notice/-/detail/20411-2025"
},
"htmlDirect": {
"BUL": "https://ted.europa.eu/bg/notice/20411-2025/html",
"SPA": "https://ted.europa.eu/es/notice/20411-2025/html",
"CES": "https://ted.europa.eu/cs/notice/20411-2025/html",
"DAN": "https://ted.europa.eu/da/notice/20411-2025/html",
"DEU": "https://ted.europa.eu/de/notice/20411-2025/html",
"EST": "https://ted.europa.eu/et/notice/20411-2025/html",
"ELL": "https://ted.europa.eu/el/notice/20411-2025/html",
"ENG": "https://ted.europa.eu/en/notice/20411-2025/html",
"FRA": "https://ted.europa.eu/fr/notice/20411-2025/html",
"GLE": "https://ted.europa.eu/ga/notice/20411-2025/html",
"HRV": "https://ted.europa.eu/hr/notice/20411-2025/html",
"ITA": "https://ted.europa.eu/it/notice/20411-2025/html",
"LAV": "https://ted.europa.eu/lv/notice/20411-2025/html",
"LIT": "https://ted.europa.eu/lt/notice/20411-2025/html",
"HUN": "https://ted.europa.eu/hu/notice/20411-2025/html",
"MLT": "https://ted.europa.eu/mt/notice/20411-2025/html",
"NLD": "https://ted.europa.eu/nl/notice/20411-2025/html",
"POL": "https://ted.europa.eu/pl/notice/20411-2025/html",
"POR": "https://ted.europa.eu/pt/notice/20411-2025/html",
"RON": "https://ted.europa.eu/ro/notice/20411-2025/html",
"SLK": "https://ted.europa.eu/sk/notice/20411-2025/html",
"SLV": "https://ted.europa.eu/sl/notice/20411-2025/html",
"FIN": "https://ted.europa.eu/fi/notice/20411-2025/html",
"SWE": "https://ted.europa.eu/sv/notice/20411-2025/html"
}
},
"winner-name": {
"swe": [
"Sandoz A/S",
"Orion Pharma Aktiebolag",
"Janssen-Cilag Aktiebolag",
"Biogen Sweden AB"
]
},
"contract-duration-end-date-lot": [
"2025-12-31+01:00"
],
"notice-title": {
"hun": "Svédország – Gyógyszerészeti termékek – Läkemedel Infliximab 2024",
"lav": "Zviedrija – Farmācijas izstrādājumi – Läkemedel Infliximab 2024",
"swe": "Sverige – Läkemedel – Läkemedel Infliximab 2024",
"gle": "An tSualainn – Pharmaceutical products – Läkemedel Infliximab 2024",
"ell": "Σουηδία – Φαρμακευτικά προϊόντα – Läkemedel Infliximab 2024",
"spa": "Suecia – Productos farmacéuticos – Läkemedel Infliximab 2024",
"est": "Rootsi – Ravimid – Läkemedel Infliximab 2024",
"nld": "Zweden – Farmaceutische producten – Läkemedel Infliximab 2024",
"fin": "Ruotsi – Farmaseuttiset tuotteet – Läkemedel Infliximab 2024",
"pol": "Szwecja – Produkty farmaceutyczne – Läkemedel Infliximab 2024",
"hrv": "Švedska – Farmaceutski proizvodi – Läkemedel Infliximab 2024",
"ces": "Švédsko – Léčivé přípravky a zdravotnické prostředky – Läkemedel Infliximab 2024",
"dan": "Sverige – Lægemidler – Läkemedel Infliximab 2024",
"ron": "Suedia – Produse farmaceutice – Läkemedel Infliximab 2024",
"por": "Suécia – Produtos farmacêuticos – Läkemedel Infliximab 2024",
"slk": "Švédsko – Farmaceutické výrobky – Läkemedel Infliximab 2024",
"fra": "Suède – Produits pharmaceutiques – Läkemedel Infliximab 2024",
"mlt": "L-Iżvezja – Prodotti farmaċewtiċi – Läkemedel Infliximab 2024",
"deu": "Schweden – Arzneimittel – Läkemedel Infliximab 2024",
"lit": "Švedija – Farmacijos produktai – Läkemedel Infliximab 2024",
"ita": "Svezia – Prodotti farmaceutici – Läkemedel Infliximab 2024",
"bul": "Швeция – Фармацевтични продукти – Läkemedel Infliximab 2024",
"slv": "Švedska – Farmacevtski proizvodi – Läkemedel Infliximab 2024",
"eng": "Sweden – Pharmaceutical products – Läkemedel Infliximab 2024"
},
"buyer-city": {
"mul": [
"Karlskrona"
]
}
}